KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Research & Development (2020 - 2025)

Recursion Pharmaceuticals' Research & Development history spans 6 years, with the latest figure at $95.9 million for Q4 2025.

  • For Q4 2025, Research & Development fell 2.43% year-over-year to $95.9 million; the TTM value through Dec 2025 reached $475.3 million, up 51.16%, while the annual FY2025 figure was $475.3 million, 51.16% up from the prior year.
  • Research & Development reached $95.9 million in Q4 2025 per RXRX's latest filing, down from $121.1 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $129.6 million in Q1 2025 to a low of $24.1 million in Q1 2021.
  • Average Research & Development over 5 years is $66.1 million, with a median of $61.3 million recorded in 2023.
  • Peak YoY movement for Research & Development: soared 133.32% in 2021, then fell 8.93% in 2022.
  • A 5-year view of Research & Development shows it stood at $48.3 million in 2021, then dropped by 8.93% to $44.0 million in 2022, then surged by 57.99% to $69.5 million in 2023, then soared by 41.52% to $98.3 million in 2024, then decreased by 2.43% to $95.9 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Research & Development are $95.9 million (Q4 2025), $121.1 million (Q3 2025), and $128.6 million (Q2 2025).